In conclusion, based on the collected data, we observed an association between impaired pulmonary function after neoadjuvant chemoimmunotherapy and PPCs and identified prior lung disease, post-treatment impaired pulmonary function, lymph node metastasis, and elevated preoperative IL-6 levels as high-risk factors for PPCs. Here, IL6 is linked to lung disorder.